On October 27, 2022, the first patient was successfully dosed in our NT-019-101 trial. NT-019-101 is a study of NX-019 in patients with advanced, epidermal Growth Factor receptor (EGFR) mutant cancer. The primary objectives for this trial are to investigate NX-019’s safety, pharmacokinetic and pharmacodynamic effects in patients with advanced NSCLC.
First- Patient-In (FPI) in the NT-019-101 clinical trial
October 27, 2022